Heart failure & cardiomyopathiesSecondary analysis
Effects of Tirzepatide in Obesity-Related Heart Failure with Preserved Ejection Fraction (HFpEF) by Sex
- Secondary analysis of the SUMMIT randomised trial
- subgroup analysis by sex
Authors' conclusion
Despite these differences, tirzepatide resulted in consistent benefits across multiple domains of HF severity that did not differ by sex.
Study context
- Population
- Patients with NYHA class II–IV HFpEF and body mass index (BMI) ≥30 kg/m² (obesity-related HFpEF)393 women · 338 men
- Participants
- 731 patients
- Comparison
- Tirzepatide vs placebo, in women and men
- Tirzepatiden = 364
- Placebon = 367reference
- Primary endpoint
- Time to CV death or worsening HF; change in KCCQ-CSS
- Follow-up
- 52 weeks
Primary result
As reported in the abstract
Primary outcomes by sex
- women; worsening heart failure (HF) or CV death
- HR 0.66
- men; worsening HF or CV death
- HR 0.61
- women; Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS)
- placebo-corrected improvement 8.1 points
- men; KCCQ-CSS
- placebo-corrected improvement 5.5 points
Secondary outcomes
| Outcome | placebo-corrected improvement (m) |
|---|---|
| 6MWD by sex · 52 weeks — Tirzepatide vs Placebo · women | 18 |
| 6MWD by sex · 52 weeks — Tirzepatide vs Placebo · men | 15 |
- 6MWD by sex: interaction P = 0.76
Higher waist to height ratio (WHtR) and poorer kidney function · baseline
- Associated exclusively in women
- interaction P = 0.043
Weight loss on tirzepatide and KCCQ-CSS improvement
- More strongly associated in women than men
- interaction P = 0.0058
Original publication
Effects of Tirzepatide in Obesity-Related HFpEF by Sex. JACC Heart Fail. Published 7 July 2026. doi:10.1016/j.jchf.2026.103218
Summarised from the published abstract; every number is checked against it